Pfizer Inc. is a global biopharmaceutical company headquartered in New York, founded in 1849. It discovers, develops, manufactures, and markets prescription medicines and vaccines across therapeutic areas including infectious diseases, oncology, immunology, rare diseases, and internal medicine. Its portfolio spans small‑molecule drugs, biologics, and nucleic acid–based modalities such as mRNA vaccines.
For the chemical and manufacturing value chain, Pfizer operates extensive process development and industrial-scale production capabilities, covering active pharmaceutical ingredient (API) synthesis, fermentation and cell‑culture bioprocessing, sterile injectables, and vaccine manufacturing (including fill‑finish). The company applies process chemistry, analytics, and quality systems to support global supply, and has advanced initiatives in continuous manufacturing and greener chemistry. Pfizer maintains a worldwide network of manufacturing and R&D sites and collaborates with external partners for selected intermediates and finished products. The acquisition of Seagen expanded Pfizer’s position in biologics and antibody–drug conjugates, integrating cytotoxic payloads and linker chemistries with large‑molecule manufacturing.
Also known as Pfizer, Seagen, and Seattle Genetics.
chemXplore tracks 1 project involving Pfizer.
Pfizer's role on them: Owner and Operator.
CHMP recommends approval after KEYNOTE-B15 showed event-free survival, overall survival and pathologic complete response gains; European Commission decision expected Q4 2026.
Phase III CELESTIMO showed a statistically significant, clinically meaningful progression‑free survival benefit for Lunsumio plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory FL after ≥1 prior therapy.
FDA clears PD‑1 inhibitor plus antibody‑drug conjugate regimens with enfortumab vedotin as neoadjuvant and adjuvant therapy around cystectomy for adults with muscle‑invasive bladder cancer.
First PD‑1 inhibitor plus ADC approved in EU as neoadjuvant then adjuvant therapy for cisplatin‑ineligible resectable muscle‑invasive bladder cancer.
sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.
CHMP backed perioperative regimen for cisplatin‑ineligible resectable MIBC after Phase 3 KEYNOTE‑905 showed significant EFS, OS and pCR gains; EC decision due by Q3 2026; FDA cleared Nov 2025.
FDA granted priority review for two sBLAs after Phase 3 KEYNOTE‑B15 showed EFS and OS benefit; PDUFA Aug 17, 2026. If approved, first perioperative options for MIBC regardless of cisplatin eligibility.
Approved with bortezomib+dexamethasone for adults after ≥1 prior line; DREAMM‑7: 3x PFS (36.6 vs 13.4m) and 42% lower death risk; outpatient ADC; ocular AEs manageable.
